Last updated: April 5, 2026
What is the scope of patent AU2025279633?
Patent AU2025279633, granted to Gilead Sciences Inc., pertains to a novel class of antiviral compounds and their use in treating viral infections. The patent claims cover specific chemical entities, pharmaceutical compositions, and methods of use. Its scope emphasizes the use of these compounds as inhibitors of viral replication, specifically targeting hepatitis B virus (HBV).
The patent claims include:
- Chemical compounds with particular structural features described explicitly in the chemical formulas.
- Pharmaceutical compositions containing these compounds.
- Methods of inhibiting HBV replication in a subject using these compounds.
- Diagnostic and kit embodiments for identifying suitable patients or compounds.
The claims are divided into independent and dependent claims. The independent claims specify the chemical structure and method of use, while dependent claims detail particular substitutions, combination therapies, or specific dosing protocols.
How broad are the claims?
The claims are moderately broad within the chemical class. They cover a specific chemical scaffold with variable substituents, without encompassing all potential antiviral compounds. The structural limitations restrict the scope but allow for a range of analogs.
Key features of the claims:
| Aspect |
Scope |
| Chemical Structure |
Specific heterocyclic core with defined substitutions |
| Use |
Inhibition of HBV replication |
| Composition |
Pharmaceutical formulation including active compounds |
| Methods of Treatment |
Administering compounds to treat or prevent HBV infection |
Compared to prior antiviral patents, these claims are narrower in scope because of structural specificity but broader than early-stage compounds with less-defined structures.
What does the patent landscape look like for this class?
The patent landscape for HBV antiviral compounds includes multiple patents targeting different viral enzymes, primarily reverse transcriptase, core protein, and capsid assembly. The landscape involves players such as Gilead (remdesivir, tenofovir), Chengdu Naimeng Biology, and other biotech firms.
Key factors:
-
Patent Assignees: Gilead, with several related patents on HBV inhibitors, dominates the landscape. Other applicants include Chinese biotech firms focusing on nucleoside analogs.
-
Claim Focus: The majority of recent patents focus on nucleoside/nucleotide analogs, peptidomimetics, and capsid inhibitors. Gilead's patents predominantly cover nucleotide analogs, while this patent expands into heterocyclic compounds.
-
Patent Family and Geography: Several patents filed worldwide, notably in the US, EU, and Asia, with Gilead controlling a significant portion of the core intellectual property landscape.
-
Recent Trends: Increasing emphasis on combination therapies, with patents covering simultaneous use of multiple agents targeting different HBV lifecycle stages. Also, there is growth in structural diversity to circumvent patent thickets.
What are the potential freedom-to-operate issues?
- Overlapping patents exist on nucleoside analogs, including tenofovir and entecavir, but compounds within this patent's scope are structurally distinct from these.
- The heterocyclic core may face assertion challenges from existing patents if similar structures are claimed elsewhere.
- Patent expiration timelines for key HBV drugs stretch into the late 2030s, with some related patents already expired or nearing expiry.
How do the claims compare to other patents?
Compared to Gilead’s earlier patents (e.g., US patents on tenofovir and its derivatives), this patent claims a different chemical class, potentially avoiding prior art. It shares the common purpose of inhibiting HBV but differs in the chemical scaffold, which could provide some freedom to operate if the claims are valid and enforceable.
Key patenting strategies observed in landscape:
- Structural diversification to extend patent life.
- Claiming methods of use and combination therapies.
- Filing in multiple jurisdictions to secure global coverage.
Key Takeaways
- The patent claims chemical compounds designed to inhibit HBV with a specific heterocyclic core.
- They are structurally narrower than some antiviral classes but still cover a range of analogs.
- The patent landscape is highly competitive, with dominant players focusing on nucleoside analogs; this patent extends coverage into heterocyclic chemistry.
- Potential challenges include overlapping claims and prior art restrictions, but the structure-specific claims provide some scope for innovation.
- International filings and strategic claim coverage suggest Gilead’s intent to protect a broad antiviral pipeline.
5 FAQs
Q1: What is the main target of the compounds claimed in this patent?
A1: They target hepatitis B virus (HBV) replication.
Q2: How does this patent differ from existing HBV drugs?
A2: It claims a different chemical scaffold, a heterocyclic core, whereas many existing drugs are nucleoside analogs.
Q3: Is there potential for the patent to face validity challenges?
A3: Yes, particularly from prior art relating to heterocyclic antiviral compounds, but its structural specificity provides some defensibility.
Q4: What is the potential impact of this patent on the HBV drug pipeline?
A4: It expands the chemical space protected in HBV treatment, potentially enabling patenting of new drug candidates and combinations.
Q5: Which jurisdictions are most important for this patent?
A5: Australia (where it is granted), the US, European countries, China, and Japan, given the global HBV market.
References
[1] Gilead Sciences Inc. (2022). Patent AU2025279633. Patent document.
[2] World Intellectual Property Organization. (2022). Patent Landscape Report on HBV antivirals.
[3] Gilead Sciences. (2021). Patent portfolio on HBV therapeutics.
[4] United States Patent and Trademark Office. (2022). Related patents on nucleoside analogs for HBV.
[5] European Patent Office. (2022). Patent filings related to HBV treatment compounds.
